Distinguished in Neurofibromatosis

Dr. Jason Fangusaro

Hematology | Oncology
Arthur M. Blank Hospital
2220 N Druid Hills Rd NE, 
Atlanta, GA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Distinguished in Neurofibromatosis
Arthur M. Blank Hospital
2220 N Druid Hills Rd NE, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jason Fangusaro is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Fangusaro is rated as a Distinguished provider by MediFind in the treatment of Neurofibromatosis. His top areas of expertise are Pineocytoma, Glioma, Pediatric Low-Grade Glioma (pLGG), and Pineoblastoma.

His clinical research consists of co-authoring 85 peer reviewed articles and participating in 22 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 9 articles and participated in 4 clinical trials in the study of Neurofibromatosis.

Specialties
Hematology
Oncology
Licenses
Pediatric Hematology-Oncology in GA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

Arthur M. Blank Hospital
2220 N Druid Hills Rd NE, Atlanta, GA 30329
Other Locations
Egleston Children's Hospital at Emory
1405 Clifton Rd NE, Atlanta, GA 30322

Additional Areas of Focus

Dr. Fangusaro has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children with Recurrent/progressive Medulloblastoma, Ependymoma and ATRT
A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children with Recurrent/progressive Medulloblastoma, Ependymoma and ATRT
Enrollment Status: Recruiting
Publish Date: October 21, 2024
Intervention Type: Drug
Study Drugs: Bevacizumab, Thalidomide, Celecoxib, Fenofibric Acid, Etoposide, Cyclophosphamide, Etoposide Phosphate, Cytarabine
Study Phase: Phase 2
A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug
Study Drug: Selumetinib
Study Phase: Phase 1/Phase 2
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Selumetinib, Vinblastine
Study Phase: Phase 3
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 1
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of DS-8201a (NSC# 807708) in Adolescents, or Young Adults With Recurrent HER2+ Osteosarcoma
A Phase 2 Study of DS-8201a (NSC# 807708) in Adolescents, or Young Adults With Recurrent HER2+ Osteosarcoma
Enrollment Status: Suspended
Publish Date: February 12, 2026
Intervention Type: Biological, Procedure
Study Drug: Trastuzumab Deruxtecan
Study Phase: Phase 2
A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2026
Intervention Type: Drug, Biological
Study Drugs: Cytarabine, Flotetuzumab
Study Phase: Phase 1
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Drug
Study Drug: Larotrectinib Sulfate
Study Phase: Phase 2
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Biological
Study Drug: APX005M
Study Phase: Phase 1
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
Enrollment Status: Completed
Publish Date: September 09, 2025
Intervention Type: Drug
Study Drug: Everolimus
Study Phase: Phase 2
Pediatric Neuro-Oncology Consortium (PNOC)-002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults With Recurrent/Refractory BRAFV600E- or BRAF Ins T Mutant Brain Tumors
Pediatric Neuro-Oncology Consortium (PNOC)-002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults With Recurrent/Refractory BRAFV600E- or BRAF Ins T Mutant Brain Tumors
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Drug
Study Drug: Vemurafenib
Study Phase: Early Phase 1
A Phase I and Feasibility Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine for Pediatric Patients With Newly Diagnosed Intracranial High Grade Glioma and Recurrent Resectable Intracranial High Grade Glioma and Ependymoma
A Phase I and Feasibility Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine for Pediatric Patients With Newly Diagnosed Intracranial High Grade Glioma and Recurrent Resectable Intracranial High Grade Glioma and Ependymoma
Enrollment Status: Terminated
Publish Date: February 18, 2025
Intervention Type: Radiation, Biological, Procedure
Study Phase: Phase 1
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 1
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: October 22, 2024
Intervention Type: Drug
Study Drugs: Irinotecan, Pevonedistat, Temozolomide
Study Phase: Phase 1
A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors
A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors
Enrollment Status: Completed
Publish Date: July 15, 2024
Intervention Type: Biological, Other
Study Drug: Pepinemab
Study Phase: Phase 1/Phase 2
A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors
A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: December 20, 2023
Intervention Type: Other, Drug
Study Phase: Phase 1
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Biological, Other
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase I Trial of Pomalidomide for Children With Recurrent, Progressive, or Refractory CNS Tumors
A Phase I Trial of Pomalidomide for Children With Recurrent, Progressive, or Refractory CNS Tumors
Enrollment Status: Completed
Publish Date: April 25, 2022
Intervention Type: Drug, Other
Study Drug: Pomalidomide
Study Phase: Phase 1
A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Drug
Study Phase: Phase 1
Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
Enrollment Status: Terminated
Publish Date: March 02, 2021
Intervention Type: Other, Drug
Study Phase: Phase 1
View 20 Less Clinical Trials

85 Total Publications

Head-to-head preclinical treatment design prioritizes promising therapies for neurofibromatosis type 1 optic glioma clinical translation.
Head-to-head preclinical treatment design prioritizes promising therapies for neurofibromatosis type 1 optic glioma clinical translation.
Journal: Neuro-oncology advances
Published: August 04, 2025
Similar Doctors
Distinguished in Neurofibromatosis
Dr. Erin Dunbar
Oncology
Distinguished in Neurofibromatosis
Dr. Erin Dunbar
Oncology

Piedmont Physicians Neurosurgery Atlanta

2001 Peachtree Rd NE Ste 645, 
Atlanta, GA 
 (3.8 miles away)
404-605-2050
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Erin Dunbar is an Oncologist in Atlanta, Georgia. Dr. Dunbar is rated as an Elite provider by MediFind in the treatment of Neurofibromatosis. Her top areas of expertise are Brain Tumor, Glioblastoma, Astrocytoma, and Glioma.

Advanced in Neurofibromatosis
Dr. Timothy Gershon
Hematology | Oncology
Advanced in Neurofibromatosis
Dr. Timothy Gershon
Hematology | Oncology

Center For Advanced Pediatrics-General And Thoracic Surgery

2174 N Druid Hills Rd NE, 
Atlanta, GA 
 (2.3 miles away)
404-785-5437
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Timothy Gershon is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Gershon is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis. His top areas of expertise are Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, Neurofibromatosis Type 1 (NF1), and Neurofibromatosis.

Experienced in Neurofibromatosis
Dr. Robert Castellino
Hematology | Oncology
Experienced in Neurofibromatosis
Dr. Robert Castellino
Hematology | Oncology

Office

5461 Meridian Mark Rd Ste 400, 
Atlanta, GA 
 (6.9 miles away)
404-785-1112
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Castellino is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Castellino is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis. His top areas of expertise are Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, and Ganglioglioma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fangusaro's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile